- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01167491
Study of One Protein Implicated in Wegener Disease (DAP12WEGENER)
April 20, 2015 updated by: Assistance Publique - Hôpitaux de Paris
Activating Receptors and DAP12 Protein in Wegener's Granulomatosis
The investigators recently showed an abnormal expansion of NK-like CD4+ T cells in Wegener's granulomatosis (WG), mainly in the diffuse vasculitis presentation.
These cells expressed an assortment of activating NK cell receptors and their signaling partners, in particular DAP12.
The investigators hypothesize that DAP12, or a downstream signaling target of DAP12, is the missing link between the different cell components involved in WG (neutrophils, macrophages, CD4 T cells).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators will test our hypothesis of "DAP-12 gain-of-function" by quantitative (mRNA and protein) and qualitative (DNA, signaling and cellular activation) analysis of the DAP12 signaling pathway in WG patients with localized (group 1; n=30) or diffuse WG (group 2; n=30) by comparison with patients with micro polyangitis (group 3; n=30), or with sarcoidosis ( group 4; n=30), and healthy blood donors (group 5; n=30).
Blood samples will be collected during a routine medical visit.
These results may help to design future therapeutic strategies based on modulation of specific intra-cellular pathways involved in the disease.
Study Type
Interventional
Enrollment (Actual)
138
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75010
- Medecine Interne Hôpital Saint Louis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Group 1: WG, with granulomatous lesions limited to upper airway or lungs and no evidence of generalized vasculitis ,± biopsy, ± anti-PR3 ANCA
- Group 2: WG with granulomatous lesions plus vasculitis expression (renal, neurological, skin, gut or heart involvement), ± biopsy, ± anti-PR3 ANCA
- Group 3: Necrotizing vasculitis with no granulomatous lesions, ± PAUCI immune glomerulonephritis, ± anti-MPO ANCA
- Group 4: clinical presentation compatible with sarcoidosis, ± biopsy, ± ECA elevated ± tuberculin anergy
Exclusion Criteria:
- <18 years
- Pregnancy or breastfeeding
- Absence of signed informed consent
- No affiliation to insurance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Disease group
Physiopathology
|
Blood samples will be collected during a routine medical visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
level of mRNA expression of DAP12
Time Frame: less than 24 hours
|
Measure:level of mRNA expression of DAP12 by RT-PCR in CD4+T cells, macrophages and neutrophils
|
less than 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
level of expression of DAP 12 downstream signalling proteins
Time Frame: Less than 24 hours
|
Measure: level of expression of DAP 12 downstream signalling proteins in CD4+ T cells, macrophages and neutrophils
|
Less than 24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Mathilde De Menthon,, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Actual)
November 1, 2013
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
July 12, 2010
First Submitted That Met QC Criteria
July 21, 2010
First Posted (Estimate)
July 22, 2010
Study Record Updates
Last Update Posted (Estimate)
April 21, 2015
Last Update Submitted That Met QC Criteria
April 20, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P081238
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wegener's Granulomatosis
-
Hospices Civils de LyonUnknownSystemic Wegener's GranulomatosisFrance
-
University of South FloridaBristol-Myers Squibb; University of Pennsylvania; National Institute of Arthritis... and other collaboratorsActive, not recruitingWegener's Granulomatosis | Granulomatosis With Polyangiitis | ANCA-Associated Vasculitis | Granulomatosis With Polyangiitis (Wegener's)United States, United Kingdom, Ireland, Canada, Germany
-
Hoffmann-La RocheCompletedWegener's Granulomatosis or Microscopic PolyangiitisIndia
-
Hospital for Special Surgery, New YorkRoche Pharma AG; Genentech, Inc.TerminatedGranulomatosis With Polyangiitis (Wegener's Granulomatosis)United States
-
Nordic Pharma SASTerminatedWegeners GranulomatosisCzech Republic
-
University of PennsylvaniaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedWegener's GranulomatosisUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedMycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory ConditionsVasculitis | Wegener's GranulomatosisUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Nippon Kayaku Co., Ltd.CompletedWegener's GranulomatosisUnited Kingdom, Germany, Sweden, Czech Republic, Denmark, Netherlands
-
National Institute of Allergy and Infectious Diseases...CompletedVasculitis | Wegener's GranulomatosisUnited States
Clinical Trials on Physiopathology Endpoint Classification
-
Nantes University HospitalActive, not recruitingPrematurity of FetusFrance
-
ANRS, Emerging Infectious DiseasesCompletedHIV-1 InfectionFrance
-
Lyell McEwin HospitalUniversity of AdelaideCompletedColorectal Neoplasms | Colorectal Polyp
-
Federal University of Rio Grande do SulUnknownDiabetic Macular Edema | Branch Retinal Vein Occlusion | Macular Telangiectasia | Chronic Central Serous RetinopathyBrazil
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Canada, Ukraine, Spain, United Kingdom, New Zealand, Netherlands, Bulgaria, Norway, Denmark, Czech Republic, Slovenia
-
Assistance Publique Hopitaux De MarseilleCompletedThalassemia Major (TM) | Thalassemia Intermedia (TI) | Microparticles (MP)Originating From Platelets, Endothelial Cells and MonocytesFrance
-
Columbia UniversityCenters for Disease Control and Prevention; Ministry of Health, RwandaCompleted
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...RecruitingEndometriosis | Deep Endometriosis | Ovarian Endometrioma | Bowel EndometriosisItaly
-
University of SaskatchewanCompleted
-
Retinal Consultants of ArizonaTopcon CorporationCompleted